|
CA2328457A1
(en)
|
1998-06-20 |
1999-12-29 |
Washington University |
Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
|
|
IL127773A0
(en)
|
1998-12-28 |
1999-10-28 |
Yeda Res & Dev |
Saccharide conjugates and pharmaceutical compositions comprising them
|
|
SE0201863D0
(en)
|
2002-06-18 |
2002-06-18 |
Cepep Ab |
Cell penetrating peptides
|
|
US9740817B1
(en)
|
2002-10-18 |
2017-08-22 |
Dennis Sunga Fernandez |
Apparatus for biological sensing and alerting of pharmaco-genomic mutation
|
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
CA2523672C
(en)
|
2003-04-29 |
2012-07-17 |
Avi Biopharma, Inc. |
Compositions for enhancing transport of molecules into cells
|
|
BRPI0415858A
(pt)
|
2003-10-29 |
2007-01-09 |
Sonus Pharma Inc |
compostos de medicamentos terapêuticos modificados por tocoferol
|
|
ATE498685T1
(de)
|
2004-06-28 |
2011-03-15 |
Univ Western Australia |
Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
IE20060565A1
(en)
|
2006-07-28 |
2008-02-06 |
Eurand Pharmaceuticals Ltd |
Drug delivery system based on regioselectively amidated hyaluronic acid
|
|
US20080311040A1
(en)
|
2007-03-06 |
2008-12-18 |
Flagship Ventures |
METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
|
|
US20080306001A1
(en)
|
2007-04-04 |
2008-12-11 |
Anzelika Liik |
Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
EP3443976A1
(en)
|
2007-06-29 |
2019-02-20 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
|
AU2008317566B2
(en)
|
2007-10-26 |
2014-05-01 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
WO2009102075A1
(en)
|
2008-02-13 |
2009-08-20 |
Kao Corporation |
Method for producing hippocastanaceae plant seed extract
|
|
US20110130346A1
(en)
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
US8575305B2
(en)
|
2008-06-04 |
2013-11-05 |
Medical Research Council |
Cell penetrating peptides
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
CN112574988A
(zh)
|
2008-10-24 |
2021-03-30 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
|
JP5786109B2
(ja)
|
2008-10-27 |
2015-09-30 |
プロセンサ テクノロジーズ ベー．フェー． |
Ｄｕｃｈｅｎｎｅ型筋ジストロフィーｍＲＮＡ前駆体のエクソン４５の効率的なスキッピングのための方法及び手段
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
LT2499249T
(lt)
|
2009-11-12 |
2018-12-27 |
The University Of Western Australia |
Priešprasmės molekulės ir patologijų gydymo būdai
|
|
EP2579899B1
(en)
|
2010-06-14 |
2017-03-15 |
F. Hoffmann-La Roche AG |
Cell-penetrating peptides and uses thereof
|
|
EP2394665A1
(en)
|
2010-06-14 |
2011-12-14 |
F. Hoffmann-La Roche AG |
Cell-penetrating peptides and uses therof
|
|
WO2012012467A2
(en)
|
2010-07-19 |
2012-01-26 |
Isis Pharmaceuticals, Inc. |
Modulation of nuclear-retained rna
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
US9550811B2
(en)
|
2010-12-02 |
2017-01-24 |
Bionor Immuno As |
Peptide scaffold design
|
|
WO2012090150A2
(en)
|
2010-12-27 |
2012-07-05 |
Compugen Ltd |
New cell-penetrating peptides and uses thereof
|
|
US9161948B2
(en)
*
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
WO2012150960A1
(en)
|
2011-05-05 |
2012-11-08 |
Avi Biopharma, Inc. |
Peptide oligonucleotide conjugates
|
|
CN103998458B
(zh)
*
|
2011-08-30 |
2018-10-09 |
医学研究理事会 |
具有中央疏水域的细胞穿透肽
|
|
HK1200484A1
(zh)
|
2011-09-14 |
2015-08-07 |
Translate Bio Ma, Inc. |
多聚寡核苷酸化合物
|
|
CN104428310A
(zh)
|
2012-06-26 |
2015-03-18 |
弗·哈夫曼-拉罗切有限公司 |
细胞穿透肽和鉴定细胞穿透肽的方法
|
|
RU2670488C2
(ru)
|
2012-09-13 |
2018-10-23 |
Юниверсите Де Женев |
Новые проникающие в клетку пептиды
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
KR102240217B1
(ko)
|
2012-09-25 |
2021-04-14 |
젠자임 코포레이션 |
근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
|
|
RS58529B1
(sr)
|
2013-03-14 |
2019-04-30 |
Sarepta Therapeutics Inc |
Sastavi koji preskaču egzon za tretiranje mišićne distrofije
|
|
GB201314411D0
(en)
*
|
2013-08-12 |
2013-09-25 |
Medical Res Council |
Peptide conjugates
|
|
ES2917473T3
(es)
|
2014-01-16 |
2022-07-08 |
Wave Life Sciences Ltd |
Diseño quiral
|
|
WO2015113922A1
(en)
|
2014-01-30 |
2015-08-06 |
Roche Innovation Center Copenhagen A/S |
Poly oligomer compound with biocleavable conjugates
|
|
WO2015161255A1
(en)
|
2014-04-18 |
2015-10-22 |
Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno |
Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy
|
|
RU2708237C2
(ru)
|
2014-08-22 |
2019-12-05 |
Общество с ограниченной ответственностью "НооГен" |
Модифицированные олигонуклеотиды и способ их получения
|
|
GB201421379D0
(en)
|
2014-12-02 |
2015-01-14 |
Isis Innovation Ltd And Medical Res Council |
Molecule
|
|
EP3034074A1
(en)
|
2014-12-18 |
2016-06-22 |
Universitat De València, Estudi General |
Compound for treatment of myotonic dystrophy type 1
|
|
KR20180002618A
(ko)
|
2015-03-23 |
2018-01-08 |
립타이드 바이오사이언스, 인코포레이티드 |
항균 펩티드 및 이의 사용방법
|
|
JP6817288B2
(ja)
|
2015-08-10 |
2021-01-20 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
新規な連結体及び生体分子と薬物との特異的共役におけるその使用
|
|
WO2017027848A1
(en)
|
2015-08-12 |
2017-02-16 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
|
|
EP3858993A1
(en)
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
KR102783452B1
(ko)
|
2016-06-01 |
2025-03-19 |
세르비에 아이피 유케이 리미티드 |
폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
|
|
WO2018053316A1
(en)
|
2016-09-15 |
2018-03-22 |
The Regents Of The University Of California |
Improved hybrid telodendrimers
|
|
US20200131231A1
(en)
|
2017-02-17 |
2020-04-30 |
Oxford University Innovation Limited |
Cell penetrating peptides
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
WO2019067979A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
WO2019067975A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
GB201812980D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
GB201812972D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
CN113453723A
(zh)
|
2018-12-07 |
2021-09-28 |
牛津大学科技创新有限公司 |
接头
|
|
EP3955966A1
(en)
|
2019-04-18 |
2022-02-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
EP3987029A1
(en)
|
2019-06-19 |
2022-04-27 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
US20220288218A1
(en)
|
2019-07-09 |
2022-09-15 |
The Governors Of The University Of Alberta |
Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene
|
|
GB201911403D0
(en)
|
2019-08-09 |
2019-09-25 |
Univ Oxford Innovation Ltd |
Conjugate and uses thereof
|
|
CA3211038A1
(en)
|
2021-02-12 |
2022-08-18 |
Oxford University Innovation Limited |
Cell-penetrating peptide conjugates and methods of their use
|
|
US20240189434A1
(en)
|
2021-03-12 |
2024-06-13 |
Pepgen Inc. |
Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates
|
|
WO2022192749A2
(en)
|
2021-03-12 |
2022-09-15 |
Pepgen Inc. |
Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates
|